Extension of Indication With Mature Products: Toward More Incentives Rewarding Innovation?
Mature products (MPs – marketed for 10 years or more) are widely used off label (from 15 to 35% according to studies) despite little evidence on benefit risk ratio. This exposes patients to risks or lack of efficacy and healthcare providers to liability. However manufacturers are rarely investing in R&D development for MPs. Indeed MPs…